pharmaceutical products for the treatment of central nervous system diseases and disorders; pharmaceutical products for the treatment of vertigo, dizziness, and lightheadedness; pharmaceutical products for the treatment of symptomatic neurogenic orthostatic hypotension; pharmaceutical products for the treatment of symptoms caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy; pharmaceutical products for the treatment of symptoms caused by Parkinson’s disease, multiple system atrophy, and pure autonomic failure

'atrophi':70 'autonom':43,54,73 'beta':47 'beta-hydroxylas':46 'caus':40,63 'central':7 'defici':49 'diabet':53 'diseas':10,67 'disord':12 'dizzi':20 'dopamin':45 'failur':44,74 'hydroxylas':48 'hypotens':32 'lightheaded':22 'multipl':68 'nervous':8 'neurogen':30 'neuropathi':55 'non':52 'non-diabet':51 'orthostat':31 'parkinson':65 'pharmaceut':1,13,23,33,56 'primari':42 'product':2,14,24,34,57 'pure':72 'symptom':39,62 'symptomat':29 'system':9,69 'treatment':5,17,27,37,60 'vertigo':19

THOXDRO

Owners

Goods & Services